1. Home
  2. SKY vs CRNX Comparison

SKY vs CRNX Comparison

Compare SKY & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SKY

Skyline Champion Corporation

N/A

Current Price

$78.47

Market Cap

4.0B

ML Signal

N/A

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

N/A

Current Price

$34.29

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKY
CRNX
Founded
2010
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.9B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
SKY
CRNX
Price
$78.47
$34.29
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$98.50
$76.75
AVG Volume (30 Days)
806.9K
941.5K
Earning Date
05-26-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
7.02
N/A
EPS
3.66
N/A
Revenue
$2,663,639,000.00
$1,039,000.00
Revenue This Year
$7.79
$720.10
Revenue Next Year
$3.10
$184.67
P/E Ratio
$20.55
N/A
Revenue Growth
7.26
N/A
52 Week Low
$59.44
$25.83
52 Week High
$99.17
$57.99

Technical Indicators

Market Signals
Indicator
SKY
CRNX
Relative Strength Index (RSI) 62.55 42.99
Support Level $73.67 $33.15
Resistance Level $79.32 $37.23
Average True Range (ATR) 3.20 1.31
MACD 0.99 -0.15
Stochastic Oscillator 91.00 34.00

Price Performance

Historical Comparison
SKY
CRNX

About SKY Skyline Champion Corporation

Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: